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Abstract
This paper reviews the literature on the pharmacotherapy of panic disorder, in order to address the
questions (1) what is the ﬁrst-line pharmacotherapy of choice for panic disorder?, (2) for how long should
maintenance pharmacotherapy be continued, and (3) what is the optimal approach to the treatment-
refractory patient with panic disorder. A MEDLINE search (1966–2003) was undertaken to collate random-
ized controlled trials of pharmacotherapy in panic disorder. A review of the evidence indicates that
SSRIs are currently the ﬁrst line agent of choice in panic disorder, and that pharmacotherapy should be
continued for at least 1 year. There has been relatively little research on the pharmacotherapy of treatment-
refractory panic disorder, and this area requires future attention.
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Introduction
Panic disorder (PD) with or without agoraphobia is
one of the most prevalent of the anxiety disorders. The
disorder is also accomplished by signiﬁcant morbidity
and comorbidity. Fortunately, a number of eﬀective
treatments for PD are available. This chapter focuses
on the pharmacotherapy, assessing the evidence
base in order to address questions about (1) the opti-
mal ﬁrst-line pharmacotherapy of PD, (2) the optimal
duration of pharmacotherapy, and (3) the optimal
approach to pharmacotherapy in the treatment-
refractory patient. In order to ensure that all relevant
randomized controlled trials were considered, a
MEDLINE search (1966–2003) was undertaken using the
key words ‘panic’ and ‘treatment’. In addition, recent
meta-analyses of PD, and treatment guidelines on PD
were reviewed. We begin by brieﬂy discussing the
diagnosis and target symptoms of PD.
Diagnosis
Panic attacks and agoraphobic avoidance are deﬁned
in the DSM-IV-TR (APA, 2000) as follows: A panic
attack is ‘a discrete period of intense fear or dis-
comfort, in which four or more of the following
symptoms develop abruptly and reach a peak within
10 minutes’. The symptoms listed are: palpitations,
sweating, trembling or shaking, sensations of short-
ness of breath or smothering, feeling of choking, chest
pain or discomfort, nausea or abdominal distress,
feeling dizzy or faint, derealization or depersonaliz-
ation, feeling of losing control or going crazy, fear
of dying, paresthesias and chills or hot ﬂushes.
Agoraphobia is deﬁned as: ‘anxiety about being in
places or situations from which escape might be diﬃ-
cult (or embarrassing) or in which help may not be
available in the event of an unexpected or situationally
predisposed panic attack. Agoraphobic fears typically
involve characteristic clusters of situations that in-
clude being outside the home alone, being in a crowd
or standing in a line, being on a bridge, and travelling
in a bus, train or automobile’.
Given that panic attacks and agoraphobia occur in
diﬀerent anxiety disorders, a ﬁrst issue in the assess-
ment of panic symptoms is the accurate diﬀerentiation
of PD from these other entities. DSM-IV-TR empha-
sizes that PD is diagnosed when the attacks experi-
enced are unexpected and when at least one of the
attacks has been followed by 1 month (or more) of
persistent concern about having additional attacks,
worry about the implications of the attacks or their
consequences, or a signiﬁcant change in behaviour
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related to the attacks (APA, 2000). Patients suﬀering
from social phobia or PTSDmay also suﬀer from panic
attacks, but these attacks are not unexpected. They are
related to speciﬁc situations: a diﬃcult social situation
or a situation that refers to a traumatic event.
When a patient with PD is also extremely afraid of
going into public places like shopping centres, trains,
cinemas or other situations from which escape would
be diﬃcult or in which help would not be available in
case of a panic attack, this person is said to have PD
with agoraphobia. There is an ongoing debate about
the possibility that patients suﬀer from agoraphobia
without panic attacks. In everyday clinical practice it is
found very often that severe agoraphobic avoidance
without present panic attacks only developed after the
occurrence of at least one unexpected panic attack.
Phobic behaviour is also common among patients
suﬀering from other anxiety disorders, but in these
disorders it is related to the avoidance of speciﬁc
situations that relate to that anxiety disorder, e.g. get-
ting dirty in patients suﬀering from OCD, or going
to meetings in patients suﬀering from social phobia.
A second important diagnostic issue is the diﬀer-
entiation of PD from general medical disorders. Given
the high prevalence of PD and its frequent presen-
tation in medical settings, it is important to have a high
index of suspicion for this disorder. As many as 3.5%
of the general population are estimated to suﬀer from
PD (Eaton et al., 1994; Katerndahl and Realini, 1993),
and 1-month prevalence rates are 0.7–2.2% for females
and 0.4–0.8% for males (Bijl et al., 1997; Eaton et al.,
1991). The prevalence of PD in medical specialities like
cardiology and otolaryngology is even much higher:
15% and higher percentages have been reported
(Chignon et al., 1993; Stein et al., 1994) and it is,
therefore, important to rule out PD in patients pres-
enting with unexplained physical complaints.
For agoraphobia, high prevalence rates are also
found with a 1-month prevalence for females of 4.4%,
and for males 1.6% (Bourdon et al., 1988). PD usually
develops during the third decade of life, with a mean
age of onset of 28 yr (Marks, 1987). People with panic
attacks may present to primary-care practitioners or to
a range of medical specialists. Unnecessary special
investigations are frequently ordered.
Conversely, however, a comprehensive medical
history and examination may be needed to exclude
the presence of physical disorders that can cause the
symptoms of a panic attack (Raj and Sheehan, 1987).
Well-known causes of panic-like symptoms are hy-
perfunction of the thyroid, hypoglycaemia and pheo-
chromocytoma. In general, any clinical condition that
is associated with physical signs that can occur also
during a panic attack, has the potency to provoke
anxiety. The most important mechanism for this is
probably the cognitive misinterpretation of these
bodily sensations (Clark, 1986). The use of psychoac-
tive substances like caﬀeine, cannabis or cocaine may
also produce panic attacks. Withdrawal from benzo-
diazepines or alcohol is another cause of panic symp-
toms. In all these situations, the patient should be
diagnosed not with PD, but rather with ‘anxiety dis-
order due to a general medical condition with panic
attacks/phobic symptoms’ or ‘substance-induced
anxiety disorder with panic attacks/phobic symp-
toms’. In some cases, substance abuse may be denied,
and drug screeningmay be required before an accurate
diagnosis is made.
Target symptoms in PD include not only panic at-
tacks and agoraphobia, but also comorbid symptoms
and associated impairment. PD is frequently associ-
ated with mood disorders, other anxiety disorders
(e.g. social anxiety disorder), and substance-related
disorders. The clinical relevance of diagnosing PD
with or without comorbid disorders lies in the fact
that patients with comorbidity are more severely and
chronically ill, more disabled, utilize services more
frequently and are more diﬃcult to treat (Roy-Byrne
et al., 2000). Formulated in other words, ‘comorbidity’
points to a more severe subgroup of PD. PD is
characterized by signiﬁcant distress and functional
impairment, and it is important these features are also
targeted by treatment interventions.
Treatment options
Although the pathogenesis of PD remains incom-
pletely understood, a range of eﬀective pharmaco-
logical, non-pharmacological, and combination
treatments have been developed in the past three
decades. Pharmacological treatments mainly comprise
treatment with high-potency benzodiazepines and
antidepressants. Other medications that have been
suggested for the treatment of PD include b-adrener-
gic blocking agents (e.g. propranolol), a2-adrenergic
receptor agonists (e.g. clonidine), mood stabilizers
(e.g. carbamazepine, lithium), and antipsychotic
agents. Propranolol has been found ineﬀective in con-
trolled trials, while most of these other agents have not
been studied systematically.
Behavioural and cognitive therapies have also been
found eﬀective for the treatment of PD (Bakker et al.,
1999; van Balkom et al., 1997). Questions remain about
how best to sequence and combine pharmacotherapy
and psychotherapy. In practice, they are frequently
combined, with the rationale that this may lead not
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only to symptom improvement, but also to a more
persistent recovery. Although psychodynamic psy-
chotherapeutic intervention strategies have been
developed (Milrod et al., 1997), the eﬃcacy of non-
directive therapies has not been documented in
controlled studies. Brief psychodynamic psycho-
therapy has, however, been reported to be helpful in
reducing relapse rates following treatment with an
antidepressant (Wiborg and Dahl, 1996).
In the treatment of PD, separate options for panic
attacks and agoraphobic avoidance behaviour can
be distinguished. Pharmacological and cognitive–
behavioural therapy (CBT) for panic attacks diminish
frequency and severity of panic attacks (Bakker et al.,
1999; van Balkom et al., 1997). With pharmacological
treatments, accompanying avoidance behaviour also
improves, as do comorbid general anxiety symptoms,
and, in case of treatment with an antidepressant, there
is also reduction in comorbid depressive symptoms
(van Balkom et al., 1997). Behavioural treatment
strategies without cognitive therapeutic elements, e.g.
‘exposure in vivo’, may be eﬀective in treating agor-
aphobic avoidance behaviour, but are not eﬀective for
panic attacks (van Balkom et al., 1997). In clinical
practice, pharmacological panic management is,
therefore, frequently combined with exposure in vivo.
In the remainder of this paper, we focus, however, on
pharmacotherapy.
Pharmacotherapy of PD
High-potency benzodiazepines and antidepressants
are the best studied pharmacotherapy options for PD.
The high-potency benzodiazepines (e.g. alprazolam
and clonazepam) have been extensively researched,
and appear to be more eﬀective than placebo in the
short-term treatment of this disorder (Beauclair et al.,
1994; Jonas and Cohon, 1993). Dosage of the high-
potency benzodiazepines in PD is higher than the
usual dosages used in generalized anxiety disorder
(see Table 1). Low-potency benzodiazepines like dia-
zepam may also only have an anti-panic eﬀect at
higher doses than normally prescribed for other dis-
orders like generalized anxiety disorder. When eﬀec-
tive, panic and phobia symptoms improve soon after
the administration of benzodiazepines (Burrows and
Norman, 1999).
The majority of studies investigating medication
therapy in PD have focused on treatment with anti-
depressants. Tricyclic antidepressants (TCAs), selec-
tive serotonin reuptake inhibitors (SSRIs), and ir-
reversible monoamine oxidase inhibitors (MAOIs)
have been proven to be eﬀective in PD (Bakker et al.,
2000; Gorman, 1997). These agents have a slower onset
of action than the benzodiazepines, and an initial trial
of 6–8 wk is required.
MAOIs such as phenelzine have shown eﬃcacy in
the treatment of PD, but are not used on a regular basis
since patients need to be on low-tyramine diets to
avoid hypertensive crises (Rosenberg, 1999). Within
the TCAs, both imipramine and clomipramine have
been studied (Cross National Collaborative Panic
Study, Second Phase Investigators, 1992; Papp et al.,
1997). The currently available SSRIs citalopram, es-
citalopram, ﬂuvoxamine, ﬂuoxetine, paroxetine, and
sertraline have all been proven more eﬀective than
pill-placebo in reducing symptomatology in PD
(Ballenger et al., 1998a; Black et al., 1993; Hoehn-Saric
et al., 1993; Lecrubier et al., 1997; Michelson et al.,
1998; Rapaport et al., 1998; Sharp et al., 1996; Wade
et al., 1997). The daily dosages of these antidepressants
are similar to those used in the treatment of major
depressive disorder (see Table 1).
Indeed, antidepressants that inﬂuence the sero-
tonergic system have consistently been shown to
have eﬃcacy in the treatment of PD. In contrast, data
Table 1. Start, mean and maximum dosage of drugs
eﬀective in panic disorder
Dosages (mg/d)
Start Mean Maximum
High-potency
benzodiazepines
Alprazolam 1.5 4–6 –*
Clonazepam 1 2–3 –*
Lorazepam 1 2–4 –*
SSRIs
Citalopram 10 20–30 60
Fluoxetine 20 20 60
Fluvoxamine 50 100–150 300
Paroxetine 10–20 20–40 60
Sertraline 50 100 200
TCAs
Clomipramine 25 100–150 250
Imipramine 25 100–150 300
MAOIs
Phenelzine 10 40–60 –*
Tranylcypromine 10 30–60 –*
SSRIs, Selective serotonin re-uptake inhibitors ; TCAs,
tricyclic antidepressants; MAOIs, monoamine oxidase
inhibitors.
* Only use mean dosage.
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on noradrenaline reuptake inhibitors for PD have
been less consistent. For example, in a double-blind
comparison between the SSRI ﬂuvoxamine and the
noradrenaline uptake inhibitor maprotiline, only
ﬂuvoxamine demonstrated good anti-panic properties
(den Boer and Westenberg, 1988).
Side-eﬀects that occur during the ﬁrst weeks of
treatment with antidepressants can easily be mis-
interpreted as symptoms of a panic attack, e.g. palpi-
tations, sweating and nausea. In patients unaware of
the possibility that such side-eﬀects may occur, an
apparent increase in the frequency and intensity of
panic attacks may be seen. The best way to prevent
such an outcome is to provide patients with suﬃcient
information about the working mechanisms and po-
tential side-eﬀects of antidepressants before treatment
with this agents is initiated. Early drop-out, non-
compliance and suboptimal treatment outcome can
also be enhanced with this strategy. Outcome can be
evaluated properly only after 6 wk of treatment.
Antidepressants vs. benzodiazepines
A number of studies have compared diﬀerent phar-
macological therapies for PD, with the majority of
these focusing on the comparison between anti-
depressants and benzodiazepines. These studies have
consistently found similar eﬃcacy. In the largest of
these studies, both imipramine and alprazolam were
superior to placebo for most outcome measures (Cross
National Collaborative Panic Study, Second Phase
Investigators, 1992). To date, a total of nine studies
comparing imipramine with high-potency benzodiaz-
epines (alprazolam, clonazepam) have been published
(van Balkom et al., 1995). Both classes of agent appear
eﬀective for panic and phobic symptoms. Diﬀerences
were observed in the time to response (earlier with
benzodiazepines) and drop-out rate (lower with ben-
zodiazepines). Despite these diﬀerences, intent-to-
treat analyses revealed no signiﬁcant diﬀerences in
eﬃcacy at end-point.
TCAs vs. SSRIs
Relatively few studies have compared diﬀerent anti-
depressants in PD (Bakker et al., 1999; Cassano et al.,
1988; den Boer et al., 1987; den Boer and Westenberg,
1988; Lecrubier et al., 1997; Modigh et al., 1992; Nair
et al., 1996; Seedat et al., 2003; Tiller et al., 1997; Wade
et al., 1997). In most studies, diﬀerent antidepressants
have shown equal eﬃcacy in reducing the total num-
ber of panic attacks. In particular, comparison of TCAs
and SSRIs has not found diﬀerences in eﬃcacy be-
tween these classes of medication (Bakker et al., 1999;
Lecrubier et al., 1997; Otto et al., 2001; Wade et al.,
1997). Some data suggests that SSRIs have a more
rapid onset of action than TCAs (Lecrubier et al.,
1997), and that SSRIs are associated with a lower
drop-out rate (Bakker et al., 2002).
Combination treatments
In everyday clinical practice combinations of diﬀerent
medications are frequently used, as well as combi-
nations of pharmacotherapy and CBT. However, the
number of controlled studies that include combination
treatments is disappointingly low.
The combination of a SSRI with a benzodiazepine is
particularly widely used in clinical practice. Early co-
administration of (high-potency) benzodiazepines like
alprazolam and clonazepam may prevent the initial
worsening of anxiety symptoms reported during the
ﬁrst weeks of treatment with a SSRI. The number of
well-designed studies that have investigated this
strategy is, however, limited. The most recent and
important study was carried out by Goddard et al.
(2001). They studied double-blind, placebo-controlled
co-administration of clonazepam (1.5 mg/d) with
open-label sertraline for the ﬁrst 4 wk of treatment.
Fifty patients were randomized, and 34 completed the
trial. There was no signiﬁcant diﬀerence in drop-
out rate between the sertraline/clonazepam and the
sertraline/placebo condition (25% vs. 38%). The
intent-to-treat analysis found a higher percentage of
responders in the sertraline/clonazepam group at the
end of both weeks 1 and 3 of the trial (41% and 63%) in
comparison to the sertraline/placebo-treated subjects
(4% and 32%). The authors concluded that rapid
stabilization of PD can be achieved safely with a
sertraline/clonazepam combination, supporting the
clinical utility of this type of regimen.
With respect to the combination of medication and
psychotherapy, the distinction between benzodiaz-
epines and antidepressants appears relevant. In a
large 8-wk study Marks et al. (1993) found no diﬀer-
ences in eﬃcacy between alprazolam and exposure,
alprazolam and relaxation, placebo and exposure,
and placebo and relaxation. However, there were
longer-lasting gains with exposure alone than with
alprazolam following withdrawal of the medication.
In contrast, there is evidence that SSRIs+CBT appear
more eﬀective than SSRIs alone.
Thus, in early work (de Beurs et al., 1995) using a
double-blind, placebo-controlled design, ﬂuvoxamine
followed by exposure in vivo demonstrated eﬃcacy
superior to that of psychological panic management
followed by exposure, and exposure in vivo alone.
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Similarly, a study by Sharp et al. (1996) included
conditions with combinations of placebo with CBT
and of ﬂuvoxamine with CBT and the largest and most
consistent treatment gains were found in the ﬂuvox-
amine with CBT group. Oehrberg and co-workers
(1995)investigatedparoxetine+standardizedcognitive
therapy (CT) vs. pill-placebo+CT; paroxetine+CT
was signiﬁcantly more eﬀective than placebo+CT on
nearly all eﬃcacy measures.
Meta-analyses
Since comparisons within one study between diﬀerent
pharmacotherapies are relatively scarce, additional
information on the diﬀerential eﬃcacy of diﬀerent
agents on panic attacks and agoraphobic avoidance
can arguably be derived from comparisons between
studies. These comparisons can be performed in a
quantitative manner by means of meta-analytical
methods.
Several meta-analyses comparing diﬀerent phar-
macological treatments for PD have been published
(Bakker et al., 1998; Boyer, 1995; van Balkom et al.,
1997; Wilkinson et al., 1991). More recently a number
of meta-analyses focusing on the comparison of TCAs
and SSRIs have been published (Bakker et al., 2002;
Otto et al., 2001). The most relevant results of these
studies are summarized here.
The meta-analysis of Wilkinson et al. (1991)
included 19 double-blind, placebo-controlled trials of
antidepressants (n=13) and benzodiazepines (n=6)
for patients with PD. It showed that active treatment
had a 25% greater success rate than placebo over
a mean duration of 14 wk. There were no statistic-
ally signiﬁcant diﬀerences observed between anti-
depressants and benzodiazepines.
The meta-analysis of Boyer (1995) reviewed 27
published or presented placebo-controlled, double-
blind studies of PD. The serotonin reuptake inhibitors
included clomipramine, ﬂuvoxamine, paroxetine, and
zimelidine. The comparison treatments were imipra-
mine and alprazolam. All three treatments were sig-
niﬁcantly superior to placebo in alleviating panic. The
serotonin reuptake inhibitors were also signiﬁcantly
superior to both imipramine and alprazolam. The
superiority of the serotonin reuptake inhibitors
remained, but was less pronounced, when they were
compared to the studies which used higher doses of
imipramine or alprazolam.
The meta-analysis of van Balkom et al. (1997)
evaluated the short-term eﬃcacy of benzodiazepines,
antidepressants, psychological panic management,
exposure in vivo, and combination treatments in PD
with or without agoraphobia. Included were 52 treat-
ment conditions with medication (28 high-potency
benzodiazepines, 24 antidepressants), with 1653
patients at pre-test and 1324 at post-test. Pre/post-
eﬀect size Cohen’s d were calculated within the treat-
ment conditions. Seven large treatment conditions
were used in the main analyses, including high-
potency benzodiazepines and antidepressants. Both
benzodiazepines and antidepressants were superior to
a control condition, consisting of pill-placebo, atten-
tion placebo (a non-speciﬁc conversation on a regular
base with a ‘therapist ’ that does not focus on any
speciﬁc symptom of the psychiatric disorder) and
waiting list for both panic attacks and agoraphobic
avoidance. A comparison between high-potency ben-
zodiazepines and antidepressants found no diﬀer-
ences in eﬃcacy. In this meta-analysis the combination
of antidepressants with exposure in vivo was found to
be the most potent short-term treatment of PD with
or without agoraphobia, especially with respect to
agoraphobic avoidance.
Longer-term follow-up data in the studies included
in the meta-analysis of van Balkom et al. (1997) were
reported seperately (Bakker et al., 1998). Eight studies
reported on high-potency benzodiazepines and ﬁve on
antidepressants. The results were consistent with
those of the short-term comparison.
A more recent meta-analysis exclusively focused on
the short-term eﬃcacy of SSRIs vs. TCAs (Bakker et al.,
2002). Included were 43 studies, published prior to
or during 1999 (34 randomized, nine open), including
53 treatment conditions, 2367 patients at pre-test and
1804 at post-test. Outcome was measured by the pro-
portion of patients becoming panic-free, and with pre/
post-Cohen’s d eﬀect sizes, calculated for four clinical
variables: panic, agoraphobia, depression, and general
anxiety. The results are summarized in Table 2,
and indicated no diﬀerences between SSRIs and TCAs
on any of the eﬀect sizes, with both groups of anti-
depressants equally eﬀective in reducing panic symp-
toms, agoraphobic avoidance, depressive symptoms
and general anxiety. Also the percentage of patients
free of panic attacks at post-test did not diﬀer across
treatments. As mentioned earlier, the number of drop-
outs was signiﬁcantly lower in the group of patients
treated with SSRIs (18%) vs. TCAs (31%). The main
conclusion was that SSRIs and TCAs have equal eﬃ-
cacy in the treatment of PD, but SSRIs are better
tolerated.
It can be concluded from these data that treatment
with antidepressants may result in complete remission
of both panic attacks and agoraphobic avoidance.
Addition of exposure in vivo may help to overcome
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agoraphobic avoidance that does not respond to
monotherapy with medications (van Balkom et al.,
1997).
First-line pharmacotherapy for PD
There are two categories of medications with suﬃcient
evidence to support their use as a ﬁrst-line treatment
for PD: high-potency benzodiazepines and anti-
depressants. There are several reasons for choosing
antidepressants rather than benzodiazepines. Perhaps
the most important is the adverse eﬀect proﬁle of
the benzodiazepines, including problems with with-
drawal. Furthermore, in contrast to antidepressants,
benzodiazepines are not eﬀective in reducing the de-
pressive symptomatology that often accompanies PD
(van Balkom et al., 1997). Finally, the risk of relapse or
recurrence of PD after discontinuation of the benzo-
diazepines is relatively high. It is not surprising,
therefore, that antidepressants have become the ﬁrst-
line pharmacotherapy of choice in the treatment of PD.
The relative eﬃcacy of diﬀerent groups of anti-
depressants in the treatment of PD and related symp-
toms is, however, still a matter of debate (Bakker et al.,
2002; Otto et al., 2001). To date, no diﬀerences in eﬃ-
cacy have been demonstrated between the two groups
of antidepressants that are used most frequently,
SSRIs and TCAs (Bakker et al., 2002; Otto et al., 2001).
However, there are indications that the drop-out rate
diﬀers signiﬁcantly in favour of the SSRIs (Bakker et
al., 2002). Drop-outs may occur for diﬀerent reasons,
varying from ineﬀectiveness to serious side-eﬀects.
The lower drop-out rate of SSRIs is most likely due to a
more tolerable side-eﬀect proﬁle. Side-eﬀects of TCAs
may also prevent therapeutic doses of these drugs
being given. Taken together, this has led to a pre-
ference for SSRIs over TCAs in both clinical practice
and in consensus guidelines (Ballenger et al., 1998b;
Bandelow et al., 2002).
There is no data that show clear advantages of one
of the SSRIs over the others. All six that are currently
available (citalopram, escitalopram, ﬂuvoxamine, ﬂu-
oxetine, paroxetine, and sertraline) have been found to
be eﬀective in the treatment of PD in double blind,
placebo-controlled trials.
During the ﬁrst weeks of treatment with a SSRI it
may be helpful to add a low dose of a high-potency
benzodiazepine (alprazolam, clonazepam) as an ad-
ditional medication (Goddard et al., 2001). This may
result in more rapid stabilization and higher response
rates during the ﬁrst weeks of treatment. The risk of
an initial worsening of anxiety symptoms is probably
Table 2. Characteristics of treatment conditions and eﬀect-sizes at post-test
TCAs N* SSRIs N*
Treatment conditions 30 23
Male/female ratio 0.50 n=25 0.51 n=22
Age (¡S.D.) 34.4 (¡4.1) n=26 35.5 (¡5.4) n=22
Illness duration (yr) (¡S.D.) 8.4 (¡2.8) n=22 9.6 (¡1.0) n=13
Weeks of treatment (¡S.D.) 9.7 (¡4.7) n=30 9.6 (¡2.7) n=22
Number of patients
Pre-test 1059 n=30 1308 n=23
Drop-out (%) 327 (31%#) n=30 236 (18%#)
Completer 732 1072
Patients free of panic attacks 304/510 n=16 539/985 n=18
at post-test (%) (60%) (55%)
Panic
d (¡S.D.) 1.46 (¡0.84) n=20 1.26 (¡0.41) n=9
Agoraphobia
d (¡S.D.) 1.15 (¡0.50) n=15 1.10 (¡0.49) n=11
Depression
d (¡S.D.) 1.25 (¡0.69) n=13 1.41 (¡0.99) n=13
Anxiety
d (¡S.D.) 1.27 (¡0.58) n=16 1.55 (¡0.84) n=16
d, Cohen’s d eﬀect size; S.D., standard deviation.
* Number of treatment conditions providing data with respect to this item.
# x2=32.8, d.f.=1, p<0.001
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reduced by this regimen as well. The main problem
that may result from prescribing a benzodiazepine as a
co-medication is that patients refuse to stop taking this
agent. This may lead to dependency and other prob-
lems related to long-term use of benzodiazepines. In
our clinical practice we mention the possibility of
taking a benzodiazepine during the ﬁrst 2 or 3 wk of
treatment with an antidepressant. We tell the patients
that they can decide themselves whether they want
this co-medication, but that the duration of the
prescription is strictly limited to 3 wk.
It has been suggested that the treatment of PD
requires a lower starting dose of the antidepressant
compared with depression to prevent an initial
worsening of symptoms and reduce the rate of drop-
out due to adverse eﬀects. In patients who have pre-
viously been unable to tolerate a standard dose of
antidepressant medication, this would certainly seem
a rational approach. However, explaining to the
patient that such a regimen may be associated with a
delayed response, may lead to the patient to choose to
start a therapeutic dose sooner. In such cases, patients
should be made aware of the possibility of early
transient side-eﬀects, and the possibility of lowering
the dose to help cope with these.
How long should maintenance pharmacotherapy
be continued?
As PD runs a chronic course, long-term treatment
outcome may be more important than short-term eﬃ-
cacy. CBT appears to have long-term beneﬁts, and
generally, the short-term results are maintained.
Naturalistic follow-up studies of psychotherapy have
been published as long as 9 yr after short-term treat-
ment (Emmelkamp et al., 1992).
The long-term eﬀect of psychopharmacological
treatments for PD has received less attention. A major
clinical problem is the fact that treatment gains
may disappear after tapering oﬀ the medication.
This is perhaps especially true for the high-potency
benzodiazepines. Relapse rates up to 80% have
been reported following complete withdrawal from
alprazolam (Noyes et al., 1991).
There is relatively little data that addresses the
optimal duration of pharmacotherapy for PD.
Mavissakalian and Perel (1992) reported that when
responders to a 6-month trial of imipramine were
treated at half-dose for another 6 months, they main-
tained their improvement. This group of patients
showed signiﬁcantly lower relapse rates than a group
of patients treated with imipramine for 6 months only.
These data suggest that successful pharmacotherapy
should be continued for at least 1 yr. There are also
papers that have reported positively on long-term
treatment with the SSRIs ﬂuoxetine and paroxetine
(Lydiard et al., 1998; Michelson et al., 1999). Important
consensus guidelines have reached the conclusion that
medication should be taken for at least 1 yr (Ballenger
et al., 1998b; Bandelow et al., 2002).
Nevertheless, a more recent paper by the same
authors (Mavissakalian and Perel, 2002) concluded
that neither the duration of treatment with imipramine
nor the method of discontinuation were predictors
of relapse. In this study, the rate of relapse after only
6 months of treatment was identical to the rate of
relapse after 12–30 months of treatment. The main
limitation of these ﬁndings is the limited sample
size: only 51 patients were included in the analyses.
Relapse prevention for patients who want to dis-
continue their medication can potentially be enhanced
by the addition of psychotherapy. An interesting
study by Wiborg and Dahl (1996) reported that
patients treated with clomipramine plus brief
psychodynamic psychotherapy had signiﬁcantly
lower relapse rates 18 months after treatment than
patients treated with clomipramine alone. Research on
long-term treatment and discontinuation of therapies
requires more attention, for pharmacotherapy as well
as psychotherapy. The conﬂicting results of the limited
data that are available with respect to the optimal
duration of pharmacotherapy underlines this need.
What is the optimal approach to the
treatment-refractory patient?
Despite advances in the pharmacotherapy of PD, not
all patients respond to the ﬁrst trial of medication.
Unfortunately, there is very little persuasive data with
respect to this topic. We suggest that when an SSRI
fails, irrespective of the reason, a second SSRI is a
Table 3. Treatment options for refractory patients
Step 1*
SSRI (for at least 4 wk in a therapeutic dosage)
Step 2*
Another SSRI
Step 3*
Tricyclic antidepressant (clomipramine or imipramine)
Step 4
High potency benzodiazepine (in a high dosage)
Step 5*
Monoamine oxidase inhibitor
* Early co-administration of clonazepam or alprazolam may
be considered.
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reasonable next step to take next. Co-medication with
a benzodiazepine, preferably a high-potency benzo-
diazepine like alprazolam or clonazepam, can also be
considered on a case by case basis, depending on the
clinician’s judgement.
If a second SSRI is not eﬀective, then a third choice
of medication may be a TCA, e.g. clomipramine or
imipramine. Such an agent can also be combined with
a benzodiazepine. Subsequent options for pharmaco-
logical treatment of refractory patients include a high
dose of high-potency benzodiazepines (up to 6 mg
alprazolam or the equivalent), and treatment with
an irreversible MAOI, e.g. phenelzine.
The addition of CBT to non- or partial medication
responders should also be considered. Table 3
summarizes the strategies in case of non-response to
ﬁrst-line pharmacotherapy.
Conclusion
When untreated, PD may run a chronic course, with a
waxing and waning of symptoms. The high preva-
lence and signiﬁcant disability associated with PD, as
well as the frequent co-occurrence of PD with mood
disorders and substance abuse disorders underline the
importance of having eﬀective treatments available.
Fortunately, recent decades have witnessed the
development of a number of eﬀective treatments,
including psychopharmacological interventions.
With regard to the short-term treatment of PD,
several standard pharmacological and psychological
interventions show equal eﬃcacy in reducing panic,
agoraphobia and related complaints. Nevertheless,
SSRIs are increasingly viewed as a pharmacotherapy
of choice, partly because benzodiazepines have rela-
tively little eﬀect on the depressive symptoms that
often complicate PD. Short-term co-medication with
high-potency benzodiazepines may be a useful strat-
egy in some cases.
For both pharmacotherapy and psychotherapy it is
still unclear how long treatment should be continued,
in what dose medication should optimally be con-
tinued after remission of symptoms has been
achieved, and what the optimal approach to refractory
patients is. After withdrawal of short-term benzodiaz-
epine and antidepressant treatment there are rela-
tively high percentages of relapse. Data for valid
comparisons of the diﬀerences in relapse between
diﬀerent medication classes is not yet available.
With regard to the combination of diﬀerent treat-
ment strategies, there is some evidence that the com-
bination of an antidepressant and exposure in vivo
produces the largest treatment gains in PD.
Agoraphobic behaviour in particular may respond
well to this combined strategy. It is, however, unclear
how long and at what dosage the medication should
be continued, and what the optimal duration and
frequency of the exposure treatment is.
Another important issue that remains to be fully
resolved is the costs that accompany diﬀerent treat-
ment strategies. Drop-out due to adverse side-eﬀects
of medication, lack of eﬃcacy, lack of compliance and
relapse after cessation of medication are important
factors that increase the total cost of treatment with
pharmacological agents. Psychotherapeutic inter-
ventions also have associated costs. Further work on
the cost-eﬃcacy of the treatment of PD is required.
In the interim, we suggest that when patients suﬀer
from panic attacks with no or only limited avoidance
then treatment of ﬁrst choice is an SSRI, but that when
patients suﬀer from agoraphobic avoidance due to
their panic attacks, exposure should be added. Our
advice is to give the antidepressant ﬁrst, and start
formal exposure after the ﬁrst positive eﬀects of the
medication have occurred. The antidepressant should
be continued at least 9 months after maximal eﬃcacy
has been attained. Psychotherapy should continue
throughout this whole period, and can be stopped
after patients have been free of medication for at least
some months.
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